Authors

Latest:

Dana Jacoby on How a Group of Physicians Can Become a Successful Medical Group

Dana Jacoby, senior consultant, BSM Consulting, gives advice on how a group of physicians can build a strong, healthy culture when looking to form a successful medical organization.

Dana M. Chase, MD, FACOG

Latest:

Emerging ADCs in Advanced Endometrial Cancer: Anti-TROP2 and Anti-FR Agents

Panelists discuss recent data on emerging antibody-drug conjugates in advanced and recurrent endometrial cancer, including anti-TROP2 agents like sacituzumab govitecan from the TROPiCS-03 trial, datopotamab deruxtecan from TROPION-PanTumor03, and sacituzumab tirumotecan, as well as anti–folate receptor agents like luveltamab tazevibulin and rinatabart sesutecan, while offering future perspectives and closing thoughts on the evolving role of these agents in the treatment landscape for endometrial cancer.

Dana Monroe, RN, BSN

Latest:

Dana Monroe on Yervoy Side Effect Nurse Self-Education

Dana Monroe from San Francisco Oncology Associates on Yervoy Side Effects and How Oncology Nurses Can Self-Educate

Danelle James, MD, MAS

Latest:

Dr. James on Update of Ibrutinib for Chronic Lymphocytic Leukemia

Danelle James, MD, MAS, head of Oncology at Pharmacyclics, assistant adjunct professor in the Division of Hematology-Oncology at the Chronic Lymphocytic Leukemia Research Consortium, discusses the RESONATE-2 study of ibrutinib (Imbruvica) versus chlorambucil through 5 years of treatment.

Daneng Li, MD

Latest:

Importance of Real-World Data in Supporting Treatment Options

Panelists discuss the insights from real-world data on the effectiveness of cabozantinib, regorafenib, and ramucirumab in second-line treatment for unresectable hepatocellular carcinoma, highlighting the differences between strict eligibility criteria and more flexible modified criteria in patient selection.

Daniel A. Barocas, MD, MPH, FACS

Latest:

Dr. Barocas on Adjuvant Sunitinib in Renal Cell Carcinoma

Daniel A. Barocas, MD, MPH, FACS, discusses adjuvant TKI therapy in patients with renal cell carcinoma at high risk of recurrence following cytoreductive nephrectomy.

Daniel A. Hamstra, MD, PhD

Latest:

Dr. Hamstra on Length of Radiation Treatments for Patients With Prostate Cancer

Daniel A. Hamstra, MD, PhD, assistant professor of Radiation Oncology, University of Michigan Health System, discusses clinical trials comparing the length of radiation treatments for patients with prostate cancer.

Daniel A. Osman, MD

Latest:

Dr. Osman on the 29th Miami Breast Cancer Conference

Dr. Daniel Osman, the program chair for the Miami Breast Cancer Conference, Discusses the 29th Annual Meeting

Daniel A. Pollyea, MD

Latest:

Dr. Pollyea on Indications for Anti-CD33 Therapy in AML

Daniel Pollyea, MD, MS, discusses indications for anti-CD33 therapy in the treatment of patients with acute myeloid leukemia.

Daniel A. Pollyea, MD, MS University of Colorado School of Medicine

Daniel B. Costa, MD, PhD, MMSc

Latest:

Dr. Costa on Biomarkers Beyond PD-L1 for Immunotherapy in NSCLC

Daniel B. Costa, MD, PhD, MMSc, associate professor of medicine at Harvard Medical School, medical staff, Hematology/Oncology, medical director of the Cancer Clinical Trials Office, and Medical Center Thoracic Oncology Group Leader, of Beth Israel Deaconess Medical Center, discusses biomarkers beyond PD-L1 in development for immunotherapy in patients with non–small cell lung cancer (NSCLC).

Daniel Catenacci, MD, University of Chicago Medicine

Latest:

Dr. Catenacci on Navigating HER2 Testing in Gastric/GEJ Cancer

Daniel Catenacci, MD, discusses navigating HER2 testing in gastric and gastroesophageal adenocarcinoma.

Daniel Costin, MD

Latest:

Dr. Costin on Initial Considerations in Early-Stage Lung Cancer

Dan Costin, MD, discusses initial considerations in early-stage lung cancer.

Daniel DeRemer

Latest:

Patient Education on Oral Chemotherapy

Daniel DeRemer, PharmD, assistant director of Clinical Therapeutics and Incubator, discusses patient education on oral chemotherapy.

Daniel Dosoretz MD

Latest:

Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter Validation

Rapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.

Daniel E. Dosoretz, MD

Latest:

Changes in Prostate Cancer Presentation for Radiation Oncology Care

USPSTF guidelines may have decreased the number of patients presenting with prostate cancer for radiation oncology care, particularly those with low-risk disease, without a short-term increase in higher-risk disease.

Daniel Eidelberg Spratt, MD

Latest:

Dr Spratt on Uncertainties Regarding Treatment Intensification in High-Risk Prostate Cancer

Daniel Spratt, MD, discusses ongoing debate and uncertainties regarding the optimal use of treatment intensification in high-risk prostate cancer.

Daniel F. Hayes, MD

Latest:

Dr. Hayes on the Future of Biomarkers for Breast Cancer

Daniel F. Hayes, MD, professor at the University of Michigan Comprehensive Cancer Center, discusses the future of biomarkers for patients with breast cancer.

Daniel G. Coit, MD

Latest:

Dr. Coit on the Evolving Role of Surgery in Patients With Melanoma

Daniel G. Coit, MD, FACS, surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of surgery in treating patients with melanoma.

Daniel G. Haller, MD, FACP, FRCP, Perelman School of Medicine